519 related articles for article (PubMed ID: 20923624)
1. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
3. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
4. Regulatory issues in pediatric psychopharmacology.
Laughren TP
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects in women: implications for drug development and regulatory policies.
Parekh A; Fadiran EO; Uhl K; Throckmorton DC
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):453-66. PubMed ID: 22114855
[TBL] [Abstract][Full Text] [Related]
6. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
7. Drug-review deadlines and safety problems.
Carpenter D; Zucker EJ; Avorn J
N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
[TBL] [Abstract][Full Text] [Related]
8. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
9. How drugs are developed and approved by the FDA: current process and future directions.
Ciociola AA; Cohen LB; Kulkarni P;
Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
[TBL] [Abstract][Full Text] [Related]
10. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
11. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
13. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
15. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
16. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
17. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
Weaver J; Grenade LL; Kwon H; Avigan M
Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
[TBL] [Abstract][Full Text] [Related]
18. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
[TBL] [Abstract][Full Text] [Related]
19. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
[TBL] [Abstract][Full Text] [Related]
20. Innovative strategies for early clinical R&D.
Butz RF; Morelli G
IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
